阿那莫林(Adlumiz)价格一览

Introduction: Anamorelin (Adlumiz) is an oral small molecule drug whose pharmacological effects are similar to ghrelin, which is the endogenous ligand of growth hormone secretagogue receptor 1a (GHS-R 1a). Anamorelin (Adlumiz) was first approved in Japan for the treatment of cancer cachexia, which is characterized by weight loss and anorexia.

A list of the prices of Anamorelin (Adlumiz) original drug and generic drugs

The original drug is produced by Ono Pharmaceuticals of Japan. The original drug is more expensive. The current price is about 4300$-4800$ per box. A common manufacturer of generic Anamorelin (Adlumiz) drugs is Lucius Pharmaceuticals of Laos. The price of this version of Anamorelin (Adlumiz) is approximately between $3,000 and $3,400.

The above is for reference only. The actual price of Anamorelin (Adlumiz) may vary due to market changes, purchasing channels and other factors. If you need to obtain the latest price information, it is recommended to contact the drug supplier or a formal medical institution. At the same time, when purchasing anamulin, whether it is an original drug or a generic drug, it is recommended to go through formal channels to ensure the quality and safety of the drug.

Therapeutic effect of Anamorelin (Adlumiz)

Anamorelin (Adlumiz) is a selective agonist of GHS-R 1a, which can enhance GHS-R 1a-mediated pituitary GH secretion and increase food consumption, thus leading to weight gain. Two phase II studies in Japan in patients with non-small cell lung cancer (NSCLC)-related cancer cachexia showed improvements in lean body mass (LBM) and relief of weight loss and anorexia.

The tumor types of the target patients in the Japanese phase III study were colorectal cancer, gastric cancer and pancreatic cancer. The results observed maintenance and increase of LBM and weight, as well as an improvement in anorexia, and confirmed the efficacy in cancer cachexia related to colorectal cancer, gastric cancer and pancreatic cancer. No events considered to pose significant safety risks were observed. In conclusion, anamorelin (Adlumiz) provides a new treatment option for cancer cachexia for which there is currently no effective treatment.